Answers are grounded in this paper and cite their sources.
Post-fracture osteoporosis drug therapy reduces the risk of subsequent fractures, while intravenous zoledronic acid has also been shown to reduce mortality. However, limited data describe racial/ethnic differences in post-fracture treatment initiation. We evaluated overall and racial/ethnic differences in osteoporosis treatment initiation within two years of an incident fracture among older women and assessed whether age or comorbidity modified these disparities. Using Medicare fee-for-service claims from May 2010 to December 2019 (with baseline data from January 2009), 722,022 women who were fracture-, diagnosis-, and treatment-naïve in the year before their fracture were followed from the date of fracture to the earliest of: first claim for osteoporosis treatment (Medicare Part B/D), loss of coverage, death, censoring at two years or end of study. Overall, 62,890 (8.7%) women-initiated treatment; the two-year Kaplan-Meier probability of treatment initiation was highest among Asian American/Pacific Islanders (16.8%; 95%CI: 15.9%-17.7%) and lowest among non-Hispanic Blacks (7.0%; 95%CI: 6.6%-7.3%). In adjusted cause-specific Cox models, compared with non-Hispanic Whites, treatment initiation was higher among Asian American/Pacific Islanders (hazard ratio [HR]=1.51; 95%CI: 1.43-1.60), Hispanics (HR=1.34; 95%CI: 1.26-1.41), and First American/Alaska Natives (HR=1.14; 95%CI: 1.04-1.26), and lower among non-Hispanic Blacks (HR=0.65; 95%CI: 0.62-0.68). Greater comorbidity burden modified the non-Hispanic Black versus non-Hispanic White disparity, which was larger among women with a Charlson Comorbidity Index (CCI) ≥1 (HR=0.62; 95%CI: 0.59-0.65) than in those with CCI=0 (HR=0.73; 95%CI: 0.67-0.80). Age did not modify the association; however, a disparity was observed between non-Hispanic Blacks and non-Hispanic Whites at ages 65-74 (HR=0.63; 95%CI: 0.58-0.67) and 75-84 years (HR=0.63; 95%CI: 0.58-0.68), attenuating at ≥85 years (HR=0.73; 95%CI: 0.66-0.80). In this nationwide cohort of older US women, non-Hispanic Black women were least likely to receive osteoporosis treatment post-fracture. These gaps may contribute to subsequent disparities in post-fracture outcomes and warrant investigation of patient-, clinician-, and system-level barriers.
No takes yet. Share an insight, caveat, or question.
Kirk et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: